11 results on '"Hudes G"'
Search Results
2. Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer.
- Author
-
Haas N, Roth B, Garay C, Yeslow G, Entmacher M, Weinstein A, Rogatko A, Babb J, Minnitti C, Flinker D, Gillon T, and Hudes G
- Subjects
- Adenocarcinoma secondary, Administration, Oral, Aged, Aged, 80 and over, Anaphylaxis etiology, Antineoplastic Combined Chemotherapy Protocols adverse effects, Chemical and Drug Induced Liver Injury, Disease Progression, Disease-Free Survival, Drug Resistance, Neoplasm, Edema chemically induced, Humans, Infusions, Intravenous, Male, Middle Aged, Nausea chemically induced, Thrombophlebitis chemically induced, Treatment Outcome, Adenocarcinoma drug therapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Estramustine administration & dosage, Gonadotropin-Releasing Hormone agonists, Paclitaxel administration & dosage, Prostatic Neoplasms drug therapy
- Abstract
Objectives: To exploit the favorable dose intensity and safety profile of weekly paclitaxel, we conducted a Phase I trial of paclitaxel by 3-hour infusion in combination with estramustine phosphate (EM) in men with hormone-refractory prostate cancer (HRPC). The antimicrotubule drug combination of paclitaxel by 96-hour infusion plus EM is active in HRPC., Methods: Twenty-four patients with metastatic HRPC and progressive tumor after antiandrogen withdrawal were enrolled in this study. Oral EM was taken at a dose of 600 mg/m(2) daily for the initial 21 patients and on a reduced schedule of 280 mg twice daily for the final 3 patients. Paclitaxel was escalated from 60 to 118 mg/m(2)., Results: The major toxicities were gastrointestinal and thromboembolic complications related to daily oral dosing of EM. Of the first 21 patients, one third (n = 7) discontinued therapy within 4 weeks because of protracted nausea and/or thrombotic complications. Dose-limiting toxicities at 118 mg/m(2) paclitaxel were fatigue and hepatotoxicity. Of 13 patients with measurable soft-tissue lesions, 6 had objective partial regressions, and 9 (37.5%) of 24 patients (95% confidence interval 19.1% to 59.1%) with elevated prostate-specific antigen levels had a 50% or greater decline of at least 4 weeks' duration., Conclusions: Weekly paclitaxel at doses of 60 to 107 mg/m(2) were feasible in combination with oral EM, but daily oral EM produced unacceptable toxicity. On the basis of these results, a Phase II trial of weekly paclitaxel with the reduced dose and schedule of EM was initiated by the Eastern Cooperative Oncology Group to assess further the benefits and risks of this treatment in men with metastatic HRPC.
- Published
- 2001
- Full Text
- View/download PDF
3. Paclitaxel and docetaxel in prostate cancer.
- Author
-
Obasaju C and Hudes GR
- Subjects
- Antineoplastic Agents, Phytogenic pharmacology, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Apoptosis drug effects, Carboplatin administration & dosage, Chemotherapy, Adjuvant, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Dexamethasone administration & dosage, Docetaxel, Drug Administration Schedule, Drug Resistance, Neoplasm, Enzyme Inhibitors administration & dosage, Enzyme Inhibitors pharmacology, Enzyme Inhibitors therapeutic use, Estramustine administration & dosage, Etoposide administration & dosage, Genes, bcl-2, Humans, Hydrocortisone administration & dosage, Male, Mitosis drug effects, Mitoxantrone administration & dosage, Multicenter Studies as Topic, Neoplasm Proteins antagonists & inhibitors, Neoplasm Proteins genetics, Neoplasm Proteins metabolism, Oligodeoxyribonucleotides, Antisense therapeutic use, Paclitaxel administration & dosage, Paclitaxel pharmacology, Palliative Care, Protein Processing, Post-Translational drug effects, Proto-Oncogene Proteins c-bcl-2 antagonists & inhibitors, Signal Transduction drug effects, Survival Analysis, Treatment Outcome, Tubulin metabolism, Adenocarcinoma drug therapy, Antineoplastic Agents, Phytogenic therapeutic use, Microtubules drug effects, Paclitaxel analogs & derivatives, Paclitaxel therapeutic use, Prostatic Neoplasms drug therapy, Taxoids
- Abstract
Although their ultimate value in prostate cancer therapy remains to be defined in randomized trials, docetaxel and paclitaxel are active agents in HRPC. Combination therapies using either of these taxanes plus oral EMP show reproducible antitumor activity that appears to be greater and more durable than that of single-agent treatment. Although the optimal combination and schedule have not been determined, weekly paclitaxel and EMP and docetaxel given every 3 weeks or by weekly infusion with EMP are useful treatment options for patients with progressive HRPC. The gastrointestinal toxicity of EMP has been reduced by intermittent rather than continuous administration, and other toxicities may be reduced further by use of intravenous EMP. Although there has been progress, the median time to progression of 5 to 6 months for current taxane-based therapies suggests that they will not have major impact on overall survival for patients with HRPC. Greater benefit may be possible earlier in the course of prostate cancer, and the activity of the taxane-EMP combinations is sufficient to justify clinical trials of adjuvant or neoadjuvant chemotherapy for selected groups of patients with locally advanced and poor-prognosis tumors. Armed with many new molecularly targeted agents that may interact favorably with taxanes, it should be possible to build on current antimicrotubule regimens to improve activity in HRPC. Taxane-EMP combinations provide a platform on which to test additional agents that may enhance the apoptotic response or circumvent cellular stress adaptations that confer drug resistance. Further elucidation of signaling pathways that regulate microtubule dynamics and programmed cell death after exposure to microtubule inhibitors would provide a more rational guide for integrating specific inhibitors of signal transduction with current taxane-based therapies. Pharmacokinetic and pharmacodynamic studies will play a key role in the development of future taxane-based therapies for prostate cancer.
- Published
- 2001
- Full Text
- View/download PDF
4. Phase II pilot study of combined chemohormonal therapy with doxorubicin and estramustine in metastatic prostate cancer.
- Author
-
Haas NB, Manola J, Hudes G, Citrin DL, Kies MS, and Davis TE
- Subjects
- Adenocarcinoma secondary, Doxorubicin administration & dosage, Estramustine administration & dosage, Humans, Male, Pilot Projects, Prostatic Neoplasms pathology, Survival Analysis, Adenocarcinoma drug therapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Neoplasms, Hormone-Dependent drug therapy, Prostatic Neoplasms drug therapy
- Abstract
Twenty-nine patients with progressive hormone-refractory metastatic adenocarcinoma of the prostate were treated with daily estramustine phosphate at 10 mg/kg, and I.V. doxorubicin 50 mg/m2 every 3 weeks. Twenty-six patients were evaluable. Four of seven patients with nonosseous measurable disease had partial responses lasting 3 to 10 months. Eleven of 19 patients with osseous metastases had stable disease or improvement on bone scan, 6 of these for 7 months or longer. Median time to progression was 20 weeks, and the median survival was 43 weeks.
- Published
- 2000
- Full Text
- View/download PDF
5. Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma.
- Author
-
Vaishampayan U, Glode M, Du W, Kraft A, Hudes G, Wright J, and Hussain M
- Subjects
- Aged, Depsipeptides, Humans, Male, Middle Aged, Neoplasm Metastasis, Adenocarcinoma drug therapy, Antineoplastic Agents therapeutic use, Oligopeptides therapeutic use, Prostatic Neoplasms drug therapy
- Abstract
Dolastatin-10 is a natural, cytotoxic peptide with microtubule-inhibitory and apoptotic effects. It has demonstrated in vitro and in vivo efficacy in the DU-145 human prostate cancer model. A Phase II clinical trial was designed in patients with hormone-refractory prostate cancer. Dolastatin-10 was administered at a dose of 400 microg/m2 i.v. every 3 weeks. Dose escalation to 450 microg/m2 was permitted. Toxicity evaluation was conducted every 2 weeks, and assessment of response was done at the end of every two cycles. Sixteen patients were enrolled between October 1998 to December 1999. The median age was 71 years (range, 59-79 years). Median prostate-specific antigen value was 108 ng/ml (range, 15.3-1672 ng/ml). Of the 15 eligible patients, 7 were Caucasian and 8 were African-American. Eight patients had bone-only metastases, and seven had measurable disease with or without bone metastases. A total of 56 cycles have been administered. Only 2 patients required dose adjustment because of toxicity, and in 5 patients, dose escalation was feasible to 450 microg/m2. The major toxicities observed were grade 3 and 4 neutropenia in 8 patients and grade 3 neuropathy in 1 patient. All 15 patients are evaluable for response. Three patients demonstrated stable disease; 2 of these had bone disease, and 1 had nodal metastasis. All others had disease progression. Dolastatin-10 is very well tolerated in this elderly, pretreated population but lacks significant clinical activity as a single agent.
- Published
- 2000
6. Preliminary results of a bone marrow magnetic resonance imaging protocol for patients with high-risk prostate cancer.
- Author
-
Freedman GM, Negendank WG, Hudes GR, Shaer AH, and Hanks GE
- Subjects
- Clinical Protocols, Humans, Male, Radionuclide Imaging, Retrospective Studies, Risk Factors, Adenocarcinoma diagnosis, Adenocarcinoma secondary, Bone Marrow diagnostic imaging, Bone Marrow pathology, Bone Neoplasms diagnosis, Bone Neoplasms secondary, Magnetic Resonance Imaging, Prostatic Neoplasms pathology
- Abstract
Objectives: To compare the accuracy of a bone marrow magnetic resonance imaging (MRI) protocol in patients at high risk of metastatic disease with radioisotopic bone scans, the standard method for detection of bony metastases in patients with prostate cancer., Methods: The study group consisted of 19 men with prostate cancer who underwent a bone marrow MRI between November 1993 and February 1996. This protocol images the marrow of the thoracolumbar spine, sacrum, pelvis, and femurs. Indications for MRI included an equivocal bone scan and/or staging of locally advanced or recurrent disease. The findings on MRI and bone scan were compared and the results correlated with the subsequent clinical patient outcome., Results: The bone marrow MRI protocol detected metastatic disease in 1 (7%) of 13 patients with negative bone scans. Four patients had an indeterminate bone scan: 2 had true-positive MRIs, 1 a true-negative MRI, and 1 a false-positive MRI on the basis of subsequent clinical follow-up. Two patients with positive bone scans had true-positive MRIs., Conclusions: Although not recommended for routine staging, MRI was useful in this study for clarifying an equivocal bone scan. The bone marrow MRI protocol images a high yield volume of the bony skeleton and is fast and economical compared with obtaining many focused MRI scans of these areas separately. These preliminary data suggest that further investigation of its clinical utility for staging locally advanced or recurrent disease is justified.
- Published
- 1999
- Full Text
- View/download PDF
7. 5-Fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer: an Eastern Cooperative Oncology Group phase II study (E1889).
- Author
-
Berlin JD, Propert KJ, Trump D, Wilding G, Hudes G, Glick J, Burch P, Keller A, and Loehrer P
- Subjects
- Aged, Aged, 80 and over, Antimetabolites, Antineoplastic administration & dosage, Fluorouracil administration & dosage, Humans, Male, Middle Aged, Survival Analysis, Adenocarcinoma drug therapy, Antidotes administration & dosage, Antimetabolites, Antineoplastic therapeutic use, Fluorouracil therapeutic use, Leucovorin administration & dosage, Neoplasms, Hormone-Dependent drug therapy, Prostatic Neoplasms drug therapy
- Abstract
This report is a multi-institutional phase II study designed to obtain the response rate, survival, and toxicity profile for patients having hormone-refractory prostate cancer. Patients who had bidimensionally measurable prostate carcinoma in first or second remission after previous hormonal therapy but no history of chemotherapy were eligible. Patients were treated with leucovorin, 20 mg/m2 intravenously, followed by 5-fluorouracil (5-FU), 425 mg/m2 intravenously daily for 5 days, with cycles repeated every 28 days. Of 38 eligible patients, 3 (7.9%) had partial responses to therapy and 20 (52.6%) had stable disease. Median survival was 11.6 months for all 38 patients and median time to progression was 4.4 months. Most of the serious side effects were gastrointestinal or hematologic and overall, 23 of 38 patients (60.5%) experienced at least one grade 3 or 4 treatment-related toxicity of any type, as measured by the National Cancer Institute common toxicity criteria. Five patients (13.2%) withdrew from the study because of adverse reactions from chemotherapy. We conclude that treatment of hormone-refractory prostate cancer patients with 5-FU and leucovorin chemotherapy produced few responses at the cost of significant side effects. Further investigation of this combination is not warranted in this setting.
- Published
- 1998
- Full Text
- View/download PDF
8. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.
- Author
-
Hudes GR, Nathan F, Khater C, Haas N, Cornfield M, Giantonio B, Greenberg R, Gomella L, Litwin S, Ross E, Roethke S, and McAleer C
- Subjects
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Alkylating administration & dosage, Antineoplastic Agents, Hormonal administration & dosage, Antineoplastic Agents, Phytogenic administration & dosage, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Disease-Free Survival, Drug Administration Schedule, Estramustine administration & dosage, Humans, Infusions, Intravenous, Male, Middle Aged, Paclitaxel administration & dosage, Survival Analysis, Treatment Outcome, Adenocarcinoma drug therapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Prostatic Neoplasms drug therapy
- Abstract
Purpose: To evaluate the antitumor activity of 96-hour paclitaxel and daily oral estramustine phosphate (EMP) in patients with metastatic hormone-refractory prostate cancer (HRPC)., Patients and Methods: Thirty-four patients with adenocarcinoma of the prostate that progressed after one or more hormonal therapies and a trial of antiandrogen withdrawal were enrolled onto this phase II trial. Patients received paclitaxel 120 mg/m2 by 96-hour intravenous (i.v.) infusion on days 1 through 4 of each 21-day cycle, together with daily oral EMP 600 mg/m2/d, continuously., Results: Four of nine patients with measurable disease had objective responses (one complete response [CR] and three partial responses [PRs]) in liver (two patients) or nodes (two patients) of 2, 6, 8, and 20 months' duration. Of 25 assessable patients with metastases limited to bone, 14 had a > or = 50% decline in pretreatment prostate-specific antigen (PSA) level sustained for at least 6 weeks and seven had a > or = 80% decline. Overall, 17 of 32 patients (53.1%) with elevated pretreatment PSA levels had a > or = 50% decline of PSA and nine (28.1%) had a > or = 80% decrease. The main toxicities (> or = grade 2) were nausea, fluid retention, and fatigue, which occurred in 33%, 33%, and 24.2% of patients. Median time to progression, based on increasing PSA level and other clinical criteria, was 22.5 weeks. The estimated median overall survival time is 69 weeks., Conclusion: The combination of EMP and 96-hour paclitaxel is an active regimen for patients with HRPC. These results further support the therapeutic strategy of combining agents that impair microtubule function by complementary mechanisms.
- Published
- 1997
- Full Text
- View/download PDF
9. Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer.
- Author
-
Hudes GR, Nathan FE, Khater C, Greenberg R, Gomella L, Stern C, and McAleer C
- Subjects
- Adenocarcinoma diagnosis, Adenocarcinoma secondary, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Diarrhea chemically induced, Drug Administration Schedule, Drug Resistance, Neoplasm, Estramustine administration & dosage, Fatigue chemically induced, Hematologic Diseases chemically induced, Hormones pharmacology, Humans, Male, Nausea chemically induced, Paclitaxel administration & dosage, Prostate-Specific Antigen analysis, Prostatic Neoplasms diagnosis, Treatment Outcome, Adenocarcinoma drug therapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Prostatic Neoplasms drug therapy
- Abstract
Combination antimicrotubule therapy with estramustine phosphate (EMP) and vinblastine has reproducible activity in metastatic hormone-refractory prostate cancer (HRPC) with an objective response rate of 31%. Although paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) by 24-hour infusion was inactive in HRPC, 0.5 to 1.0 nmol/L concentrations of paclitaxel combined with EMP exerted synergistic cytotoxicity in DU-145 androgen-independent human prostate cancer cell lines. Based on these results, we treated 24 patients with HRPC using the combination of paclitaxel 120 to 140 mg/m2 by 96-hour intravenous infusion every 3 weeks plus daily oral EMP at 600 mg/m2/d. Of seven patients with measurable soft tissue metastases, three have attained partial responses and a fourth patient is nearing partial response status. Of 16 patients with bone-only disease evaluated by change in serum prostate-specific antigen levels, 11 patients (68.8%) have had decreases of > or = 50% from pretreatment baseline. The prostate-specific antigen decrease has exceeded 80% in six of 16 (37.5%) patients. For all 23 evaluable patients, the prostate-specific antigen has decreased by > or = 50% in 15 (65.2%) and by > or = 80% in eight (34.7%). Grade 4 leukopenia occurred in one of 21 patients treated at the paclitaxel dose of 120 mg/m2/96 hr and one of three patients treated at 140 mg/m2/96 hr. The incidence of nausea (50%) and peripheral edema (37.5%) was similar to that associated with single-agent EMP. These results demonstrate that 96-hour paclitaxel plus EMP is active in HRPC and provide further evidence that the rational combination of antimicrotubule agents leads to synergistic antitumor activity in HRPC.
- Published
- 1995
10. Preservation of immune effector cell function following administration of a dose-intense 5-fluorouracil-chemotherapy regimen.
- Author
-
Weiner LM, Hudes GR, Kitson J, Walczak J, Watts P, Litwin S, and O'Dwyer PJ
- Subjects
- Adenocarcinoma blood, Adenocarcinoma drug therapy, Antibody-Dependent Cell Cytotoxicity drug effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Aspartic Acid analogs & derivatives, Aspartic Acid pharmacology, Colorectal Neoplasms blood, Colorectal Neoplasms drug therapy, Dose-Response Relationship, Drug, Fluorouracil administration & dosage, Humans, Immunity, Cellular drug effects, Immunity, Cellular immunology, Interleukin-2 pharmacology, Killer Cells, Natural drug effects, Killer Cells, Natural immunology, Leukocytes, Mononuclear drug effects, Leukocytes, Mononuclear immunology, Lymphocytes drug effects, Lymphocytes immunology, Monocytes drug effects, Monocytes immunology, Phenotype, Phosphonoacetic Acid analogs & derivatives, Phosphonoacetic Acid pharmacology, Adenocarcinoma immunology, Colorectal Neoplasms immunology, Fluorouracil pharmacology, Immunosuppressive Agents pharmacology
- Abstract
In a phase II clinical trial of 5-fluorouracil (5FU) plus N-(phosphonacetyl)-L-aspartate (PALA) therapy administration, a number of slowly developing clinical responses were observed. Because of this, a variety of immune parameters were sequentially studied in 21 patients on this trial. Of the 21 patients studied, 20 provided sufficient samples to compare baseline with subsequent values, 10 of the 20 patients responded to treatment. Responders and non-responders did not differ in any studied parameter at baseline. After 2 months of therapy, non-specific monocyte cytotoxicity (NSMC), antibody-dependent monocyte cytotoxicity (ADMC) and natural killer (NK) activity were higher in the entire study population, but these increases were not statistically significant. When responders and non-responders were evaluated separately, it was apparent that the trend was due solely to the changes observed in the responding patient population. When mean lysis values for each patient group were determined for each studied time point, it was possible to generate a mean area under the cytotoxicity/time curve (AUC) for each studied parameter. NSMC and ADMC did not differ in responders and non-responders. However, NK activity was significantly greater by mean AUC analysis (P = 0.006) in the responding group; NK activity was maintained in the responders, but decreased in non-responders. When lymphocyte and monocyte expression of the surface markers beta 2-microglobulin, HLA-DR, CD56, HNK-1, CD16 and interleukin-2 receptor were evaluated, there were no differences among responders and non-responders at baseline by mean AUC analysis or when comparing baseline with non-baseline values. It is concluded that although baseline immunological characteristics do not identify patients who are likely to respond to weekly 5FU and PALA, treatment is not associated with deleterious effects on the immune effector function parameters evaluated in this study, there being no effects on expression of a variety of associated cell-surface molecules.
- Published
- 1993
- Full Text
- View/download PDF
11. Phase II study of amonafide (nafidamide, NSC 308847) in advanced colorectal cancer.
- Author
-
O'Dwyer PJ, Paul AR, Hudes GR, Walczak J, Ozols RF, and Comis RL
- Subjects
- Adenine, Antineoplastic Agents administration & dosage, Antineoplastic Agents adverse effects, Drug Evaluation, Humans, Isoquinolines adverse effects, Middle Aged, Naphthalimides, Organophosphonates, Adenocarcinoma drug therapy, Antineoplastic Agents therapeutic use, Colorectal Neoplasms drug therapy, Imides, Isoquinolines therapeutic use
- Abstract
Amonafide, a benzisoquinoline-1,3-dione with anti-tumor activity in preclinical screens, was administered to patients with recurrent or metastatic bidimensionally measurable colorectal cancer. Fourteen patients with no prior chemotherapy for advanced disease, performance status 0-1, and normal bone marrow, renal, and hepatic function were entered. Amonafide 300 mg/m2 was administered intravenously over 1 hour daily for five consecutive days; courses were repeated every three weeks. The major side effect was neutropenia: Grade 3 or 4 toxicity occurred in 5/14 patients. Other toxicities included nausea and vomiting, flulike symptoms, fever, rash and alopecia. Three patients had stable disease, but there were no responses observed. Amonafide at this dose and schedule has no activity in the treatment of colorectal cancer.
- Published
- 1991
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.